Table 4.
Medical expenditures during the 1-year post-operation period by region for newly diagnosed ovarian cancer patients.
| Northeast | North Central | South | West | Unknown | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | (IQR) | Median | (IQR) | Median | (IQR) | Median | (IQR) | Median | (IQR) | ||
| Total | 102,055 | (68,851–150,195) | 87,468 | (56,068–130,028) | 91,140 | (60,228–137,127) | 100,536 | (65,358–148,707) | 94,561 | (71,922–138,265) | <0.001 |
| Inpatient services | 33,773 | (21,251–56,455) | 28,562 | (18,640–46,575) | 28,468 | (19,348–46,702) | 34,099 | (21,899–59,795) | 35,298 | (22,575–58,218) | <0.001 |
| Outpatient services | 54,407 | (34,190–86,283) | 47,823 | (28,015–79,216) | 53,688 | (31,201–82,487) | 55,128 | (31,469–85,646) | 59,307 | (43,112–84,737) | <0.001 |
| Outpatient drugs | 2,507 | (803–5,773) | 1,668 | (522–4,282) | 1,669 | (604–3,950) | 1,577 | (482–4,109) | 2,318 | (843–5,566) | <0.001 |
OOP (out-of-pocket), insurance liability, and COB (coordination of benefits and other savings) for inpatient, outpatient services and outpatient drugs were winsorized at 3rd & 97th percentiles, then summed to get inpatient, outpatient services, outpatient drugs, and total medical expenditures (including inpatient, outpatient services and outpatient drugs).